Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch"). GENova expects to generate licensing fees and royalties from the out-licensed manufacturing and marketing rights to leading pharmaceutical companies to exceed more than 5% in a market currently valued at $3billion+ a year over the following 15-20 years which is the duration of the patents.

Bridge BioResearch is an international drug discovery company that focuses on metabolic disorders, and has well-established distribution channels and relationships with leading pharmaceutical companies.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

The two companies are both in the business of acquiring early-stage developmental drugs, out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Bridge BioResearch specializes in Obesity and Type 2 Diabetes drugs. Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Big Pharma such as Biogen, Elan, Merck's and Genentech.

"This reciprocal arrangement is a huge benefit to both companies," says Aaron Whiteman, CEO for GENova. "I am confident that with our new access to Big Pharma distribution channels we can usher our promising patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen."


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Andrzej Klos, ... Andrzej Klos, a board-certified pediatrician for nearly 38 years, is motivated each and every ... and commitment to his profession shine alongside his many awards and accolades, which include ...
(Date:7/29/2015)... ... ... Core Organizer ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... , Wouldn’t it be great if everyone could be a little more organized? Well ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... a sponsor, with its Topricin® Pain Relief and Healing Cream designated as the ... web-based organization that is actively addressing Line of Duty Deaths (LODD) and the ...
(Date:7/29/2015)... ... 29, 2015 , ... On July 26th the Miami ... for nicotine laced liquid products. Their report says cigarette use has decreased recently ... particularly troublesome to addiction professionals as many of the candy flavors available are ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Get More Organized with the Core Organizer App 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3
... the Gulf Coast Region Work Together to Prepare,Vulnerable ... 11 As Hurricane Ike,approaches the Gulf Coast, ... procedures in advance of a potential healthcare,crisis, threatening ... therapy. In preparation for this pending disaster,scenario, the ...
... the Drug Enforcement Administration explores the many costs ... and consequences of illegal drugs, LOS ... America: Opening Eyes to the Damage,Drugs Cause will open in Los ... May 3, 2009 the exhibit will explore the,science behind illegal drug ...
... MINRAD,International, Inc. (Amex: BUF ) today ... wholly-owned subsidiary of RxElite Inc. (OTC,Bulletin Board: RXEI), ... RxElite Holdings, Inc.,s rights to be the exclusive ... the United,States. Minrad has decided to move into ...
... Hurricane Ike nears the Gulf Coast, evacuating Texans are ... Red Cross Safe and Well,Web site., WASHINGTON, Sept. ... Friday evening or early Saturday morning,affecting areas of Texas ... to Texas, its message to residents is urgent: listen ...
... Minn., Sept. 11 A study led by ... published this week in,the Journal of the American ... effective., Lead author David Cook, M.D., an ... at Mayo Clinic, worked with researchers,from Mayo and ...
... GAITHERSBURG, Md. and TOKYO, Sept. 11 MedImmune, ... Co., Ltd, a,subsidiary of SBI Holdings, Inc., announced ... collaboration agreement to develop and commercialize,SBI Biotech,s anti-ILT7 ... (SLE) and other autoimmune diseases. MedImmune has,global rights ...
Cached Medicine News:Health News:Texas Home Oxygen Therapy Community Braces for Hurricane Ike 2Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 2Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 3Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 4Health News:MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc. 2Health News:MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc. 3Health News:American Red Cross Urges, 'Prepare for Ike' 2Health News:American Red Cross Urges, 'Prepare for Ike' 3Health News:Mayo Clinic, McMaster University Research Review Shows Internet-based Instruction Effective for Teaching Health Care Professionals 2Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2
(Date:7/29/2015)... July 27, 2015 Research and Markets ( ... "3D Metrology Market by Product (CMM, ODS, and VMM), ... & Geography (North America, Europe, APAC, RoW) - Global ... The 3D metrology market was valued ... grow at a rate of 7.11% during the forecast ...
(Date:7/29/2015)... Inc., a privately-held regenerative medicine company with the first stem cell-derived ... today announced the opening of a second site in its Phase ... olerability, and E fficacy of VC-01™ Combination P roduct ... the first in Canada , will be at ... Alberta.  The lead Edmonton ...
(Date:7/29/2015)... 29, 2015 According to a ... Active Pharmaceutical Ingredients (API) Market - Global Industry Analysis, ... " the global active pharmaceutical ingredients market was valued ... to reach USD 185.9 billion by 2020, expanding at ... 2014 to 2020. Full Research Report on ...
Breaking Medicine Technology:Global 3D Metrology Market 2015-2020: Products (CMM, ODS, and VMM) & Applications (Automotive, Aerospace, Energy & Power, Medical and Electronics) 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 2Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 3Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 5
... PAUL, Minn., March 7, 2012  Prime Therapeutics (Prime), a ... a leader in the U.S. biopharmaceutical market and subsidiary ... agreement bringing the first outcomes-based rebate contract for a ... As an integrated PBM with its health plan clients, ...
... WESTLAKE VILLAGE, Calif., March 7, 2012 Denise Noyer-Erez, ... Month" in honor of all those affected by the ... million women and girls in the United States.  In ... and immunological disease in which the endometrium—uterine lining—moves outside ...
Cached Medicine Technology:Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif® 2March is Endometriosis Awareness Month 2
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... Peroxidase stain is the gold standard ... better agreement with your technologists manual ... efficiency. ,True RBC morphology advances cell ... allows for the differentiation of various ...
200 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Medicine Products: